## WHAT IS CLAIMED IS:

1. A method for inhibiting HIV viral budding from a host cell, comprising reducing the concentration of a protein complex in the cell, said protein complex having a first protein which is Tsg101 interacting with a second protein which is HIV GAG.

5

2. The method of Claim 1, wherein said reducing step comprising interfering with an interaction between said first protein and said second protein.

٠

- 3. The method of Claim 2, wherein said reducing step comprises

  administering to the cell a compound capable of interfering with an interaction between said first protein and said second protein.
  - 4. The method of Claim 3, wherein said compound is capable of binding Tsg101.

15

- 5. The method of Claim 3, wherein said compound is capable of binding the UEV domain of Tsg101 protein.
- 6. The method of Claim 5, wherein said compound is an antibody immunoreactive with Tsg101.
  - 7. The method of Claim 5, wherein said compound is a nucleic acid encoding an antibody immunoreactive with Tsg101.
- 25 8. The method of Claim 7, wherein said antibody is a single-chain antibody.
  - 9. The method of Claim 5, wherein said compound is a peptide having a contiguous span of from 7 to 50 amino acid residues of HIV GAG, said contiguous span encompassing the late domain motif.

30

## Attorney Docket No. 1907.04-1

10

- 10. The method of Claim 1, wherein said reducing step comprises reducing the concentration of Tsg101 in the cell.
- The method of Claim 10, wherein said step of reducing the concentration
   of Tsg101 in the cell comprises administering to the cell a nucleic acid molecule that induce the degradation of RNA transcripts encoding Tsg101.
  - 12. The method of Claim 11, wherein said nucleic acid molecule is an antisense compound specifically hybridizing to a Tsg101 nucleic acid.
  - 13. The method of Claim 11, wherein said nucleic acid molecule is a ribozyme compound specifically hybridizing to a Tsg101 nucleic acid.
- 14. The method Claim 11, wherein said nucleic acid molecule is an siRNA or an expression vector expressing an shRNA.
  - 15. The method of Claim 13, wherein said expression vector comprises a promoter operably linked to an shRNA-encoding nucleic acid.
- 20 16. An expression vector comprising a promoter operably linked to a nucleic acid encoding an shRNA capable of inducing degradation of Tsg101 transcript.
  - 17. A host cell comprising the expression vector of Claim 16.
- 25 18. An expression vector comprising a promoter operably linked to a nucleic acid encoding an shRNA capable of hybridizing to a region of an HIV transcript encoding the GAG polypeptide, said region encoding HIV GAGp6.
  - 19. A host cell comprising the expression vector of Claim 18.